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Verapamil reverses abnormal [Ca2Ji and carbohydrate metabolism of
PMNL of dialyis patients. The basal levels of cytosolic calcium ([Ca2]i)
of polymorphonuclear leukocytes (PMNL) are elevated in hemodialysis
(HD) patients, and this abnormality has been implicated in the dysfunc-
tion of the PMNL of these patients. The elevated [Ca2]i appears to be
due to PTH-induced entry of calcium into PMNL, an action that may be
prevented by calcium channel blockers. We examined [Ca2]i and carbo-
hydrate metabolism of PMNL of normal subjects and of HD patients
before, after eight to nine weeks of verapamil therapy (120 mg/day), and
after eight to ten weeks of discontinuation of verapamil treatment. In HD
patients, the basal levels of [Ca2]i of PMNL are elevated and their
glucose uptake, the activity of total and active forms of glycogen syn-
thetase, and glycogen content are reduced compared to values in normal
subjects (P < 0.01). These derangements were normalized after verapamil
therapy and re-emerged after discontinuation of treatment with verapamil
despite no change in blood levels of PTH. The results indicate that the
elevation in [Ca2Ii of PMNL and the consequent derangements in
carbohydrate metabolism of these cells are treatable with a calcium
channel blocker. The data assign a valuable role for calcium channel
blockers for the amelioration of some aspects of cell dysfunction of
uremia.
Chronic renal failure (CRF) is a state of increased calcium
burden of cells, and this abnormality plays a paramount role in the
genesis of many of the manifestations of the uremic syndrome [1].
Indeed, in both animals [2—5] and humans [6—81 with CRF, the
basal levels of cytosolic calcium ([Ca2]i) of many cells are
elevated and the functions of these cells are disturbed.
A large body of evidence indicates that the state of secondary
hyperparathyroidism is responsible for the elevation in [Ca2Ii
[2—8]. This is not surprising since PTH augments the entry of
calcium into many cells through the activation of their L-type
calcium channels [9—12]. Verapamil, a blocker of these channels,
interferes with this action of PTH that mediates the entry of
calcium into cells [9—12].
Several studies utilized this property of verapamil to document
its usefulness in the management of the metabolic and functional
derangements of cells in animals with CRF [4, 13—18]. Indeed,
verapamil treatment of CRF rats not only prevented the elevation
in [Ca2]i and dysfunction of cells when the drug was given from
Received for publication November 7, 1994
and in revised form December 12, 1994
Accepted for publication December 29, 1994
© 1995 by the International Society of Nephrology
day one of CRF [13—18], but also reversed these derangements
when the drug was used in rats with pre-existing CRF [4, 19].
The documentation that verapamil can reverse the elevation in
{Ca2]i and the functional derangements of cells of patients with
CRF has important implications for the management of patients
with CRF. The present study examined the effect of verapamil
treatment of dialysis patients on the [Ca2]i and carbohydrate
metabolism of their polymorphonuclear leukocytes (PMNL).
Methods
Fifteen hemodialysis patients (HD) were studied. Their mean
age was 63 5.0 years. They received dialysis therapy three times
per week for three to four hours each time using a dialyzer made
of hemophane (Gambro, Hechnigen, Germany). The patients
were not receiving calcium channel blockers and did not have
evidence of infection at the time of the study. Twenty-five healthy
normal subjects (NS; 45 5.5 years of age) who were receiving no
medications served as the controls. The dialysis patients were
studied before, after eight to nine (8.2 3) weeks of treatment
with verapamil (120 mg/day given orally in one single dose) and at
eight to ten (8.6 0.4) weeks after discontinuation of the
verapamil therapy.
Blood samples were obtained before the dialysis session from
the arteriovenous fistula. The separation of the PMNL from
peripheral blood was made according to the method described by
Ferrante and Thong [20] with certain modifications. The details of
the method of separation of PMNL from blood of HD patients
and NS have been already reported from our laboratory [6].
The basal levels of [Ca2]i in PMNL was measured with fura 2
AM using a Perkin-Elmer fluorometer model LS 5B (Perkin-
Elmer, Norwalk, CT, USA). The details of this methodology have
been reported from our laboratory [4, 6]. The dissociation con-
stant for Ca2-fura 2 was assumed to be 225 m and calculation
of [Ca2]i was made using the Grykiewicz equation [21].
Glycogen synthetase was assayed in PMNL according to Tho-
mas, Schlender and Lamer [22]. The isolated PMNL were resus-
pended in Ca2 and Mg2-free phosphate buffer solution (PBS)
and adjusted to a concentration of io cells/mi. The cells were
ultrasonically disintegrated for 5 seconds. An aliquot of 50 l of
the homogenate was assayed on ice with 50 1u1 of a mixture that
contained 5 mCi/liter (3H)-uridine diphosphate (UDP) glucose,
33 mrvt Tris-HC1, 3.3 mtvt EDTA, 6.6 g/liter glycogen, 4.5 mM
UDP-glucose and with or without glucose-6-phosphate. This
mixture (with glucose-6-phosphate in a final concentration of 4.5
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Table 1. Blood biochemical parameters in normal subjects and
hemodialysis patients
Normal
Hemodialysis patients After
discontinuationBefore After
subjects verapamil verapamil of verapamil
Serum PTH 27 3.1 460 116° 444 114° 450 115°
pg/mi
Plasma 9.12 0.12 9.0 0.25 8.8 0.12 8.9 0.16
calcium
mg/dl
Plasma 3.5 0.1 5.7 0.40° 6.1 O.23a 5.8 0.33a
phosphorus
mg/dl
Plasma 1.1 0.15 9.9 0.44° 10.9 0.61° 10.3 0.51
creatinine
mg/dl
Plasma 27.6 0.43 18.1 0.66a 17.3 0.80 17.6 0.76
bicarbonate
mM/liter
Data are presented as mean 1 SE.
ap < 0.01 vs. normal subjects
mmollliter) was incubated for 20 minutes for total glycogen
synthetase activity (D + I-forms) and (without glucose-6-phos-
phate) for 60 minutes for the active form of glycogen synthetase
(independent I-form) at 37°C. After incubation, 75 j.tl of this
mixture was placed on Whatman filter paper (2 X 2 cm, Whatman
31 ET, Maidstone, UK). The filter papers were washed with 66%
ethanol, followed by a final acetone rinse. The amount of radio-
activity was determined in a liquid scintillation counter (Packard
Tri-Carb 2000, CA, USA).
Glycogen phosphorylase was analyzed in PMNL (50 l; io
cells/ml) according to the method of Slonczewski, Wilde and
Zigmond [23]. The assay procedure was the same as for determi-
nation of glycogen synthetase with one exception. The solution
(50 pA) in which the incorporation of radioactive glucose-i-
phosphate into glycogen with glycogen phosphorylase takes place
contained the following: 10 m glucose-i-phosphate, 10 g/liter
glycogen, 100 mM sodium fluoride, 66.5 mM PIPES (Sigma,
Munich, Germany), 0.5 mCi/liter 14C-glucose-i-phosphate. Total
enzyme activity was determined in the presence of 1 mM adeno-
sine monophosphate (AMP) in the solution and the active form
of phosphorylase in the absence of AMP.
Glycogen was determined in PMNL using the filter paper
technique according to Solling and Essman 24]. The PMNL
suspension of i07 cells was ultrasonically disintegrated as de-
scribed above. One hundred microliters of the homogenate was
pipetted onto 2 X 2 cm of Whatman filter paper. The paper was
washed with ice-cold 66% ethanol with a final rinse of acetone.
The dried filter paper was placed in a 15 ml tube that contained a
thoroughly mixed preparation of 300 pA of 0.1 M acetate buffer, pH
4.75 and 30 pA of aminoglucosidase (4.5 units). The mixture was
then left standing for 10 minutes at room temperature for the
degradation of glycogen. The released glucose was determined
with a commercially available assay (Merckotest' Glucose,
Merck, Darmstadt, Germany).
Hexose uptake was determined by the method described by
McCall et al [25]. PMNL were resuspended in PBS (with Ca2
and Mg2) at a concentration of i06 cells/mi. Triplicate assays
were performed in 1.5 ml test tubes that contained 200 pJ of cell
Fig. 1. Basal levels of /Ca2]i of PMNL from nonnal subjects (NS) and
hemodialysis (HD) patients. Each column represents mean value and
brackets denote I SE. Symbols are: (LI) NS; (U) before verapamil therapy;
(12) after verapamil thereapy; (B) after discontinuation of verapmail
therapy. < 0.01 versus NS and HD after verapamil therapy.
suspension and 10 1d PBS or 10 .d of 10—6 M of the stimulating
factor formyl-methionyl-leucyl-phenylalanine (FMLP) (Sigma).
PMNLs were preincubated for 15 minutes at 37°C in a shaking
water bath. Uptake was initiated by the addition of 0.5 iCi (3H)
u-glucose (10 nM). Uptake was terminated after 60 minutes by the
addition of 1 ml iced PBS; the sample were then centrifuged at
1000 x g for 20 seconds. The pellet was washed with 1 ml of iced
PBS and again centrifuged. The supernatant was removed by
aspiration, the pellet and tube were placed in a scintillation vial
containing 10 ml of Aquasone (Packard, Zurich, Switzerland).
Radioactivity was determined with a liquid scintillation counter
(Packard).
The concentration of plasma calcium, phosphorus, creatinine
and bicarbonate were measured by standard laboratory technique.
The concentration of intact PTH in serum was determined with
radioimmunoassay with the normal value being 55 pg/ml. For
analysis of significance the paired and unpaired Student's i-test
was used, and data are presented as mean 1 SE.
Results
Table 1 presents the data on the serum levels of PTH and the
plasma concentrations of calcium, phosphorus, creatinine and
bicarbonate. HD patients have significantly (P < 0.01) higher
levels of PTH, phosphorus and creatinine and lower levels of
bicarbonate than the NS. The plasma concentrations of calcium
were not different among the NS and HD patients. Treatment
with verapamil did not cause a significant change in these
parameters.
The basal levels of [Ca2 ]i in PMNL (79 5.1 nM) from HD
patients were significantly (P < 0.01) higher than those in NS (52
3.4 ntvi; Fig. 1). Treatment of HD patients with verapamil
reversed this abnormality, and the levels of [Ca2]i in PMNL after
this therapy were not different from normal (55 3.2 flM).
Discontinuation of verapamil was followed by reappearance of the
high basal levels of [Ca2t ji in PMNL (73 4.9 flM).
The FMLP-stimulated glucose uptake by PMNL from HD
patients (6209 1346 CPM/2 X 10 PMNL) was significantly (P
<0.01) lower than that by PMNL from NS (13573 1720 cpm/2
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x i0 PMNL). Treatment of HD patients with verapamil was
associated with a significant (P < 0.01) improvement in glucose
uptake, but the values (9804 1188 cpm/2 X iO PMNL) were
still lower than normal. Discontinuation of verapamil therapy was
followed by the return of glucose uptake to a level (5146 534
cpm/2 X iO PMNL) not different from that observed prior to
initiation of verapamil therapy (Fig. 2).
Figure 3 depicts the data on the total and active forms of
glycogen synthetase of PMNL from NS subjects and HD patients.
The values of both the total and active forms of glycogen
synthetase were significantly (P < 0.01) lower in HD patients (6.7
0.35 mU/106 PMNL and 68 5.9 U/106 PMNL, respectively)
than in normal subjects (9.4 0.65 mU/106 PMNL and 137 23.4
JLU 106 PMNL, respectively). Treatment of the HD patients with
verapamil reversed these abnormalities and the values of total (8.5
0.52 mU/106 PMNL) and active form (147 18.4 .tU/106
PMNL) of glycogen synthetase became normal. After discontin-
uation of verapamil therapy the values of this enzyme decreased
again to levels seen prior to therapy with verapamil (6.9 0.43
mU/106 PMNL and 75 10.9 .tU/106 PMNL, respectively).
There were no significant differences between the total and
active form of glycogen phosphorylase in NS subjects (1.55 0.05
and 0.31 0.02 mU/106 PMNL, respectively) and HD patients
(1.50 0.08 and 0.30 0.03 mU/106 PMNL, respectively).
Treatment of the dialysis patients did not cause a significant
change in this parameter (1.65 0.07 and 0.35 0.04 mU/106
PMNL).
Glycogen content of PMNL of HD patients (16.1 1.1 jsgIlO6
PMNL) was significantly (P < 0,01) lower than that in NS (19.7
1.4 sgI106 PMNL). Treatment with verapamil reversed this
abnormality (19.9 1.4 jsgJlO6 PMNL). The glycogen content
decreased again after discontinuation of verapamil therapy (14.5
1.2 jig/106 PMNL; Fig. 4).
mentioned that Haynes et al [28] did not find an elevated [Ca2Ji
Discussion in PMNL from patients with end-stage renal failure not treated by
Our data show, as has been previously reported, that the basal HD nor from patients managed with chronic ambulatory perito-
levels of [Ca2]i of PMNL from HD patients [6, 26] and from rats neal dialysis. However, these authors did not report the actual
with chronic renal failure [4, 27] are elevated. It should be data on [Ca2ji, and did not report blood levels of the PTH in
Fig. 2. Increments in glucose uptake by PMNLs from normal subjects (NS)
and hemodialysis patients (HD). Each column represents mean value and
bracket denotes 1 SE. Symbols are in Figure 1. < 0.01 versus NS and
HD after verapamil therapy.
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Fig. 3. The values of total (A) and active form (B) ofglucogen synthetase of
PMNLs from normal subjects (NS) and hemodialysis patients (HD). Each
column represents mean value and brackets denote 1 SE. Symbols are in
Figure 1. *P < 0.01 vs. NS and HD after verapamil therapy.
Fig. 4. Glycogen content of PMNLs from normal subjects (NS) and hemo-
dialysis patients (HD). Each column represents mean value and brackets
denote 1 SE. Symbols are the same as in Figure 1. < 0.01 vs. NS and HD
after verapamil therapy.
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their patients. It is possible that these levels were only mildly
elevated and hence did not affect the [Ca2]i of the PMNL of
their patient. Also the method used by these authors to measure
[Ca2]i utilized one excitation wavelength while other reports [4,
6, 26, 27] that demonstrated a rise in [Ca2]i used two excitation
wavelengths. This difference in technique may have affected the
results.
The present study demonstrate that the treatment of HD
patients with verapamil reversed the abnormalities in the [Ca2]i
of their PMNL. This finding is similar to that noted in PMNL [7]
and pancreatic islets [19] of CRF rats. Further, our results show
that the discontinuation of verapamil therapy was followed by the
reemergence of high basal levels of [Ca2]i in PMNL. This effect
of verapamil may not be unique to this drug but is shared by other
calcium channel blockers. Indeed, Raine et a! [8] reported that the
basal levels of [Ca2*]i of platelets of HD patients is significantly
elevated but HD patients treated with nifedipine have normal
levels of [Ca2]i in their platelets. Also Alexiewicz et al [261 found
that the [Ca2]i of PMNL from HD patients treated with nife-
dipine is not different from that of normal subjects, while [Ca2]i
of HD patients who were not receiving nifedipine is elevated.
Several studies have demonstrated that the elevated blood
levels of PTH in CRF causes a rise in [Ca2]i of many cells [291.
This phenomenon is due to both increased entry of calcium into
cells and decreased exit of calcium out of cells [29]. The role of
excess PTH in this phenomenon has been supported by two
observations. First, the prevention of secondary hyperparathy-
roidism by parathyroidectomy of CRF animals resulted in nor-
malization of [Ca2]i despite CRF [29]. Second, chronic admin-
istration of PTH to animals with normal renal function caused an
elevation of [Ca2]i [3, 30]. One would expect, therefore, that a
relationship between [Ca2]i and blood levels of PTH should
exist. However, we did not find such a relationship among our
fifteen patients. This is not necessarily surprizing since it has been
shown that CRF is associated with down-regulation of the PTH-
PTHrP recetors in various cells [3 1—33]. This phenomenon would
prevent continued rise in [Ca2]i as PTH levels increased further.
Thus, once a new steady state is reached with elevated [Ca2]i,
further increases in blood levels of PTH will not cause additional
rise in [Ca2]i, and hence a correlation between [Ca2]i and PTH
levels may not be observed.
Since the elevation of basal levels of [Ca2]i in cells in CRF is,
in major part, due to the PTH-induced entry of calcium into them,
agents that interfere with this action of the hormone should be
able to prevent this rise in [Ca2]i. Both verapamil [9—12] and
nifedipine [11, 12] have been shown to cause marked inhibition of
the acute PTH-induced rise in [Ca2]i of many cells; hence, their
use in animals and human with CRF should prevent and/or
reverse the rise in [Ca2]i by blocking the action of PTH on cells.
The elevation in the basal levels of [Ca2]i appears to be
deleterious to cell function. Indeed, the rise in [Ca2]i of pancre-
atic islets is associated with impaired insulin secretion [21, of brain
synaptosomes with derangements in their norepinephrine [15],
acetylcholine [18] and phospholipid metabolism [16], and of
PMNL with impaired phagocytosis [4, 6] and reduced oxygen
consumption [4] by these cells. Further, the prevention of the
elevation of {Ca2]i of these cells resulted in the normalization of
the derangements in their function despite CRF [4, 15—19].
The data of the present study provide a new and additional
example of such an association. The [Ca2]i of PMNL of HD
patients is elevated and their carbohydrate metabolism is de-
ranged. The reversal of the elevated {Ca2]i of these cells by
verapamil therapy was associated with normalization of the
abnormalities in their carbohydrate metabolism. These derange-
ments reemerged after the therapy with verapamil was discontin-
ued and when [Ca2]i of the PMNL became elevated again.
It should be mentioned that verapamil may affect [Ca2]i and
carbohydrate metabolism of PMNL by an as yet unidentified
mechanism(s). Even if such a possibility does exist, verapamil may
still mediate part of its effect through an interaction with PTH
effect on cells. Indeed, verapamil blocks the PTH-induced rise in
[Ca2]i in many cells [291, and parathyroidectomy of CRF animals
is followed by normalization of [Ca2]i and improvement in cell
function as observed with verapamil therapy.
The mechanisms through which an elevation in basal levels of
[Ca2]i exerts its deleterious effects on cells function may be
complex and are not well understood. However, available data
suggest that several possibilities may operative including reduced
ATP content of cells [29, 34], inhibition of various enzyme
activities of cells [29, 34—36] and/or interference with the molec-
ular machinery of cells [31—33].
Thus the exact pathways through which a rise in basal levels of
[Ca2]i of PMNL adversely affects their carbohydrate metabolism
are not delineated as yet. Our data, however, show that the
reduction in glycogen content of PMNL of HD patients is due to
impairment in stimulated glucose uptake by these cells and in the
activity of their glycogen synthetase. Both of these derangements
lead to decreased glycogen synthesis and, hence, reduced glycogen
content. It also appears that increased glycogenolysis do not
contribute to the reduced glycogen content of the PMNL since the
activity of the glycogen degrading enzyme, glycogen phosphory-
lase, is not altered.
Our observations are similar to those observed in rat adipocytes
with sustained elevation in [Ca2]i [34—401. The studies in rat
adipocytes have shown that the rise in their [Ca2]i renders them
resistant to insulin-induced glucose uptake. Further, the elevation
in [Ca2]i interferes with the inhibition of dephosphorylation of
the inactive form of glycogen synthetase.
The results of this study and those reported in CRF animals [4,
15—19] clearly indicate that the state of increased calcium burden
of cells in CRF is a treatable phenomenon. It could be prevented
and even reversed by calcium channel blockers. Thus, these
studies assign a valuable role for these agents in the overall
management of the patients with advances renal failure.
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